Cargando…

Quantitative analysis of phantom studies of (111)In and (68)Ga imaging of neuroendocrine tumours

BACKGROUND: Nuclear medicine imaging of neuroendocrine tumours is performed either by SPECT/CT imaging, using (111)In-octreotide or by PET/CT imaging using (68)Ga-radiolabelled somatostatin analogs. These imaging techniques will give different image quality and different detection thresholds for tum...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jönsson, L., Stenvall, A., Mattsson, E., Larsson, E., Sundlöv, A., Ohlsson, T., Hindorf, C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5818391/ https://www.ncbi.nlm.nih.gov/pubmed/29460190 http://dx.doi.org/10.1186/s40658-018-0204-0

Ejemplares similares

Correction to: Quantitative analysis of phantom studies of (111)In and (68)Ga imaging of neuroendocrine tumours
por: Jönsson, L., et al.
Publicado: (2022)

Relationships between uptake of [(68)Ga]Ga-DOTA-TATE and absorbed dose in [(177)Lu]Lu-DOTA-TATE therapy
por: Stenvall, Anna, et al.
Publicado: (2022)

Monte Carlo investigation of PET [(68)Ga]Ga-DOTA-TOC activity-administration protocols for consistent image quality
por: Kalaitzidis, Philip, et al.
Publicado: (2023)

111In-Octreoscan SPECT/CT hybrid imaging and 68Ga-DOTANOC PET/CT in neuroendocrine adenoma of the middle ear (NAME)
por: Pontico, Mariano, et al.
Publicado: (2020)

(68)Ga-DOTATATE PET/CT versus (111)In-octreotide scintigraphy in patients with neuroendocrine tumors: a prospective study
por: Cavicchioli, Marcelo, et al.
Publicado: (2022)

A [68Ga]Ga-DOTANOC PET/CT Radiomic Model for Non-Invasive Prediction of Tumour Grade in Pancreatic Neuroendocrine Tumours
por: Bevilacqua, Alessandro, et al.
Publicado: (2021)

Impact of Specific Bowel Symptoms on Quality of Life in Patients with Midgut Neuroendocrine Tumours
por: Ohlsson, Håkan, et al.
Publicado: (2021)

Quantitative γ-H2AX immunofluorescence method for DNA double-strand break analysis in testis and liver after intravenous administration of (111)InCl(3)
por: Stenvall, Anna, et al.
Publicado: (2020)

Evaluation of Cross-Calibrated (68)Ge/(68)Ga Phantoms for Assessing PET/CT Measurement Bias in Oncology Imaging for Single- and Multicenter Trials
por: Byrd, Darrin W., et al.
Publicado: (2016)

Evaluation of a (68)Ga-Labeled DOTA-Tetrazine as a PET Alternative to (111)In-SPECT Pretargeted Imaging
por: Edem, Patricia E., et al.
Publicado: (2020)

Staging of neuroendocrine tumours: comparison of [(68)Ga]DOTATOC multiphase PET/CT and whole-body MRI
por: Schraml, C., et al.
Publicado: (2013)

Cost-Effectiveness Analysis of (68)Ga DOTA-TATE PET/CT, (111)In-Pentetreotide SPECT/CT and CT for Diagnostic Workup of Neuroendocrine Tumors
por: Froelich, Matthias Frank, et al.
Publicado: (2021)

Al[(18)F]F-NOTA-Octreotide Is Comparable to [(68)Ga]Ga-DOTA-TATE for PET/CT Imaging of Neuroendocrine Tumours in the Latin-American Population
por: Haeger, Arlette, et al.
Publicado: (2023)

The Value of Somatostatin Receptor Imaging with In-111 Octreotide and/or Ga-68 DOTATATE in Localizing Ectopic ACTH Producing Tumors
por: Gözde Özkan, Zeynep, et al.
Publicado: (2013)

Meningiomas: A Comparative Study of (68)Ga-DOTATOC, (68)Ga-DOTANOC and (68)Ga-DOTATATE for Molecular Imaging in Mice
por: Soto-Montenegro, María Luisa, et al.
Publicado: (2014)

[(68)Ga]Ga-DOTA-TOC: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging
por: Hennrich, Ute, et al.
Publicado: (2020)

Current Status of (68)Ga-Pentixafor in Solid Tumours
por: Hadebe, Bawinile, et al.
Publicado: (2022)

Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours
por: Kim, Yong-il, et al.
Publicado: (2020)

Highly variable biodistribution of (68)Ga labeled somatostatin analogues (68)Ga-DOTA-NOC and (68)Ga-DOTA-TATE in neuroendocrine tumors: clinical implications for somatostatin receptor directed PET/CT
por: Cheng, Monica, et al.
Publicado: (2022)

Optimization of injected (68)Ga-PSMA activity based on list-mode phantom data and clinical validation
por: Wielaard, J., et al.
Publicado: (2020)

Gastrointestinal neuroendocrine tumor with discordant metastatic disease on 111In-pentetreotide SPECT/CT, 18F-DOPA PET/CT and 68Ga-HA-DOTATATE PET/CT
por: Resch, Katrin, et al.
Publicado: (2022)

Cyclotron-based production of (68)Ga, [(68)Ga]GaCl(3), and [(68)Ga]Ga-PSMA-11 from a liquid target
por: Rodnick, Melissa E., et al.
Publicado: (2020)

Testicular Metastasis of Jejunal Neuroendocrine Tumor on (68)Ga-DOTATATE PET/CT
por: Şahin, Ömer Faruk, et al.
Publicado: (2023)

[(68)Ga]Ga-PSMA-11: The First FDA-Approved (68)Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer
por: Hennrich, Ute, et al.
Publicado: (2021)

Whole-Body 68Ga-DOTANOC PET/MRI Versus 68Ga-DOTANOC PET/CT in Patients With Neuroendocrine Tumors: A Prospective Study in 28 Patients
por: Berzaczy, Dominik, et al.
Publicado: (2017)

(68)Ga-DOTATATE Prepared from Cyclotron-Produced (68)Ga: An Integrated Solution from Cyclotron Vault to Safety Assessment and Diagnostic Efficacy in Neuroendocrine Cancer Patients
por: Tremblay, Sébastien, et al.
Publicado: (2023)

Multicentre quantitative (68)Ga PET/CT performance harmonisation
por: Huizing, Daphne M. V., et al.
Publicado: (2019)

Comparison between (68)Ga-bombesin ((68)Ga-BZH3) and the cRGD tetramer (68)Ga-RGD(4 )studies in an experimental nude rat model with a neuroendocrine pancreatic tumor cell line
por: Cheng, Caixia, et al.
Publicado: (2011)

Searching for primaries in patients with neuroendocrine tumors (NET) of unknown primary and clinically suspected NET: Evaluation of Ga-68 DOTATOC PET/CT and In-111 DTPA octreotide SPECT/CT
por: Schreiter, Nils Friedemann, et al.
Publicado: (2014)

Impact of segmentation and discretization on radiomic features in (68)Ga-DOTA-TOC PET/CT images of neuroendocrine tumor
por: Liberini, Virginia, et al.
Publicado: (2021)

Prognostic Evaluation of Metastatic Castration Resistant Prostate Cancer and Neuroendocrine Prostate Cancer with [(68)Ga]Ga DOTATATE PET-CT
por: Bilen, Mehmet Asim, et al.
Publicado: (2022)

A first-in-human study of [(68)Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death
por: Ho Shon, Ivan, et al.
Publicado: (2022)

Grading of Neuroendocrine Carcinomas: Correlation of (68)Ga-PET/CT Scan with Tissue Biomarkers
por: Liverani, Chiara, et al.
Publicado: (2018)

Ileal Neuroendocrin Tumor Metastasis to Breast Diagnosed with Ga-68 DOTATATE PET/CT
por: Sağlampınar Karyağar, Sevda, et al.
Publicado: (2019)

Abstracts of Poster Presentations (Ga-68 Imaging)
Publicado: (2011)

Preparation and Evaluation of [(18)F]AlF-NOTA-NOC for PET Imaging of Neuroendocrine Tumors: Comparison to [(68)Ga]Ga-DOTA/NOTA-NOC
por: Dam, Johan Hygum, et al.
Publicado: (2022)

Detection of neuroendocrine tumours in the small intestines using contrast-enhanced multiphase Ga-68 DOTATOC PET/CT: the potential role of arterial hyperperfusion
por: Schreiter, Nils F., et al.
Publicado: (2014)

Current knowledge on the sensitivity of the (68)Ga-somatostatin receptor positron emission tomography and the SUV(max) reference range for management of pancreatic neuroendocrine tumours
por: Virgolini, Irene, et al.
Publicado: (2016)

Influence of Macrocyclic Chelators on the Targeting Properties of (68)Ga-Labeled Synthetic Affibody Molecules: Comparison with (111)In-Labeled Counterparts
por: Strand, Joanna, et al.
Publicado: (2013)

Evaluation of (68)Ga-Radiolabeled Peptides for HER2 PET Imaging
por: Ducharme, Maxwell, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_fi4qs9rnqvgde7fpedcv01lo4d